Zymeworks Inc., a Vancouver, BC, Canada-based biotherapeutics company focused on the development of antibody and protein-based therapeutics, completed a $8.1m financing.
Backers include existing investor CTI Life Sciences Fund, L.P. and private shareholders, as well as new investor Advanced Biotechnologies Venture Fund.
The company plans to use the capital to advance its Azymetric™ and AlbuCORE™ platforms, and its protein therapeutics pipeline in the areas of cancer, autoimmunity and inflammatory diseases.
Led by President and CEO Dr. Ali Tehrani, Zymeworks and CFO Neil Klompas, Zymeworks. hs developed a proprietary structure-guided protein engineering technology (ZymeCAD™) and novel Azymetric™ and AlbuCORE™ platforms, which enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.
FinSMEs
22/09/2011